Épisodes

  • Pharmaceutical Executive Daily: BioNTech Files Patent iInfringement Lawsuit Against Moderna

    Pharmaceutical Executive Daily: BioNTech Files Patent iInfringement Lawsuit Against Moderna
    Feb 20 2026
    In today’s Pharmaceutical Executive Daily, BioNTech files a patent infringement lawsuit against Moderna, the Supreme Court rules against a large number of Trump-era tariffs, and the FDA approves a Calquence–venetoclax combination for certain blood cancers.
    Afficher plus Afficher moins
    2 min
  • Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals

    Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals
    Feb 19 2026
    In today’s Pharmaceutical Executive Daily, the FDA reportedly removes its two-study requirement for new drug approvals, Hims & Hers enters a $1 billion agreement to acquire Eucalyptus, and experts examine how FDA can help ease early-stage clinical trial bottlenecks.
    Afficher plus Afficher moins
    2 min
  • Pharmaceutical Executive Daily: FDA Initiates Review of Moderna’s Seasonal Influenza Vaccine

    Pharmaceutical Executive Daily: FDA Initiates Review of Moderna’s Seasonal Influenza Vaccine
    Feb 18 2026
    In today’s Pharmaceutical Executive Daily, the FDA begins reviewing Moderna’s seasonal flu vaccine under a revised regulatory approach, Eli Lilly signs a $100 million licensing agreement with CSL for an anti- IL-6 monoclonal antibody., and Southern Florida emerges as a growing biotech hub.
    Afficher plus Afficher moins
    2 min
  • Pharmaceutical Executive Daily: FDA Approves New Dosing Schedule for Rybrevant Faspro

    Pharmaceutical Executive Daily: FDA Approves New Dosing Schedule for Rybrevant Faspro
    Feb 17 2026
    In today’s Pharmaceutical Executive Daily, the FDA approves a monthly dosing schedule for Rybrevant Faspro, HHS Secretary Robert F. Kennedy Jr. revises the agency’s leadership team, and industry expert Sandy Tammisetty discusses what it takes to deliver actual value in today’s pharmaceutical landscape.
    Afficher plus Afficher moins
    2 min
  • Pharmaceutical Executive Daily: Disc Medicine Receives CRL from FDA for Bitopertin

    Pharmaceutical Executive Daily: Disc Medicine Receives CRL from FDA for Bitopertin
    Feb 16 2026
    In today’s Pharmaceutical Executive Daily, the FDA issues a Complete Response Letter for Disc Medicine’s bitopertin in EPP, Edwards Lifesciences lifts its anti-copycat policy, and industry leaders examine how to scale global medical digital transformation while ensuring local fit.
    Afficher plus Afficher moins
    2 min
  • Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron

    Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron
    Feb 13 2026
    In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and a former AstraZeneca executive is charged with multiple offenses in China.
    Afficher plus Afficher moins
    1 min
  • Pharmaceutical Executive Daily: FDA Issues Refusal-to-File Letter to Moderna

    Pharmaceutical Executive Daily: FDA Issues Refusal-to-File Letter to Moderna
    Feb 11 2026
    In today’s Pharmaceutical Executive Daily, the FDA issues a refusal-to-file letter to Moderna for its seasonal influenza vaccine as the company secures a long-term agreement in Mexico, industry leaders assess China’s evolving role in global pharma strategy, and the FDA makes a decision on Keytruda in platinum-resistant ovarian cancer.
    Afficher plus Afficher moins
    2 min
  • Pharmaceutical Executive Daily: Specialized Wealth Management for BioPharmaceutical Sales

    Pharmaceutical Executive Daily: Specialized Wealth Management for BioPharmaceutical Sales
    Feb 10 2026
    In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisory services, QuantX Biosciences and Pandorum Technologies close Series B financing rounds, and Iambi enters a $1 billion collaboration with Takeda to advance small-molecule programs.
    Afficher plus Afficher moins
    2 min